Overview

Open-Label Extension Study of Rufinamide Given as Adjunctive Therapy in Patients With Refractory Partial Seizures

Status:
Terminated
Trial end date:
2010-05-14
Target enrollment:
Participant gender:
Summary
This was an open-label extension study in adolescent and adult (between 12 and 80 years old) participants who had completed their participation in Study E2080-A001-301. The main objective of this study was to evaluate the safety and efficacy of long-term administration of rufinamide for the control of epileptic seizures in participants who had refractory partial seizures despite treatment with a maximum of three approved antiepileptic drugs (AEDs).
Phase:
Phase 3
Details
Lead Sponsor:
Eisai Inc.
Treatments:
Rufinamide